Published in Medical Letter on the CDC and FDA, February 19th, 2006
According to the review, "In the next decade, we should witness a number of treatment advances for opioids, stimulants, and cannabis derivatives. For opioids, this will include long acting, i.e., one month to one year, injectable or implants of the antagonist naltrexone, injectable or implants of the partial agonist buprenorphine, and innovative detoxification methods using buprenorphine."
"In addition, there should be much wider office based prescribing of buprenorphine for maintenance as financial, stigma, and numerical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.